Whistleblower
Champions for the courageous
who report fraud.
Our nation’s whistleblower laws embody the wisdom that ordinary Americans are oftentimes best positioned to monitor and report on fraud.
Overview
Whistleblowers play an important role in exposing illegal activity and holding companies that defraud the federal and state governments accountable. We represent individuals who report fraud and pursue whistleblower claims under federal and state false claims acts and other fraud reporting programs including the whistleblower programs of the Securities and Exchange Commission, Commodity Futures Trading Commission, and Internal Revenue Service.
We work on claims involving:
- Securities & Investment Fraud
- Health Care Fraud
- Government Contractor/Procurement Fraud
- Tax Fraud
Confidentiality
Reporting fraudulent activity can seem like a risky endeavor. We understand the stress and uncertainty that comes with deciding to report fraud. Be assured, when you entrust us with information about potentially fraudulent activity, your confidentiality is of paramount concern throughout our initial consultation and investigation. And we take appropriate measures to protect your confidentiality during any litigation concerning your whistleblower claims.
We represent:
- Private citizens such as physicians, nurses, stockbrokers, financial analysts, engineers, scientists, medical coders, sales representatives, accountants, and data analysts who have witnessed their company, or a company whose operations they have reason to know, engage in fraudulent billing or other fraudulent conduct while providing goods or services being paid for, in whole or in part, with government funds.
- Businesses that have learned that their competitors are engaged in fraudulent schemes directed against the government. Sometimes these schemes are intended to give the competitor an unfair advantage in soliciting government business, thus triggering potential overlapping antitrust violations.
We represent clients on a contingency fee basis, and we do not charge a fee for an initial, no-obligation case evaluation that is fully confidential. We carefully evaluate each claim whistleblowers bring forward, heavily investing our time and resources to demonstrate our belief in a case’s value. We receive a fee only when we succeed on your behalf.
If the government intervenes in your case and recovers funds the corporate wrongdoer obtained through fraud or financial damages from the company, you may receive a whistleblower award, ranging from 15% – 30% of any amount recovered. These awards are meant to incentivize whistleblowers to step forward, alert the government to fraud, and assist the government in recovering the funds obtained through fraud.
Fraud can be reported, and awards received, anonymously. While it is not necessary for a whistleblower to engage legal counsel at the time of reporting fraud, misconduct, or other violations, it is recommended.
Not all misconduct is covered by whistleblower reward law. The false claims statutes and each whistleblower program’s law define the scope of covered misconduct, the type of individual who may be eligible for a reward, and mandatory procedures for reporting. Qualifying for and receiving a reward under these laws requires a careful understanding of and adherence to these rules. Our experienced whistleblower attorneys stand ready to assist.
Current Cases
U.S. ex rel. Pepe M.D. and Sherman, M.D. v. Fresenius Vascular Care, Inc., et al.
In 2022, the federal government and multiple state governments intervened in this qui tam action commenced by Cohen Milstein on behalf of the whistleblowers against Fresenius Vascular Care, Inc. and affiliated defendants, alleging that they violated the federal and state False Claims Acts by performing and billing Medicare and Medicaid for unnecessary surgical procedures that were not covered by these programs, that subjected patients to health risks, and that defrauded the government and taxpayers of many millions of dollars. The action seeks treble damages and civil penalties.
U.S.A. v. Janssen Biotech, Inc.
U.S.A. v. Janssen Biotech, Inc. (D. Mass.): Cohen Milstein represents the plaintiff-relator in a whistleblower/qui tam lawsuit against Janssen Biotech (a subsidiary of Johnson & Johnson), alleging that the manufacturer of the rheumatoid arthritis drugs Remicade and Simponi ARIA violated federal law by engaging in a scheme through which it provided physicians free practice management and infusion business consulting services over an extended period to induce the physicians to purchase Remicade and Simponi ARIA and administer these drugs to patients, including Medicare beneficiaries, via infusions performed in their offices.
Past Cases
COVID-19 Waiver Program FCA Litigation
United States et al., ex rel. Bay Area Whistleblower Partners v. ReNew Health Group LLC et al. (C.D. Cal.): Cohen Milstein represented whistleblowers in a lawsuit alleging that ReNew Health, which owns and operates dozens of nursing facilities throughout California, submitted millions of dollars of false claims to Medicare and California Medicaid under the COVID-19 waiver program for skilled care beginning at the start of the pandemic in March 2020. The whistleblower lawsuit prompted an investigation by the U.S. Department of Justice and the California Department of Justice’s Division of Medi-Cal Fraud and Elder Abuse. This investigation culminated in the first False Claims Act settlement regarding fraud in the COVID-19 Waiver Program, totaling more than $7 million.
Commonwealth of Pennsylvania v. International Business Machines Corp.
Commonwealth of Pennsylvania v. International Business Machines Corp. (Crt. Common Pleas, Dauphin Cnty., Penn.): Cohen Milstein represented the Commonwealth of Pennsylvania, Department of Labor and Industry in a breach of contract dispute against IBM related to the modernization of an unemployment compensation delivery system for the Commonwealth. On August 24, 2021, the parties announced, after extensive discovery and the exchange of expert reports, that they had reached a confidential settlement.
USA, State of Maryland ex rel. J. Doe v. Shore Health System, Inc.
United States of America and The State of Maryland ex rel. J. Doe v. Shore Health System, Inc. (D. Md.): Cohen Milstein represented the whistleblower who brought forward and filed a qui tam lawsuit, alleging that Shore Health System, a subsidiary of the University of Maryland Medical System that operates two hospitals and several non-hospital outpatient centers located on Maryland’s Eastern Shore, overcharged the Medicare and Maryland Medicaid programs between 2014 – 2018 for services provided to Medicare and dual eligible Medicare and Medicaid beneficiaries. On July 16, 2021, the Maryland U.S. Attorney’s Office and the State of Maryland reached a $9.5 million settlement.